BIIB 080
Alternative Names: BIIB080; IONIS BIIB4RX; IONIS MAPTRx; IONIS-MAPTRX; ISIS 814907Latest Information Update: 02 Apr 2026
At a glance
- Originator Ionis Pharmaceuticals
- Developer Biogen; Ionis Pharmaceuticals
- Class Antidementias; Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action Gene silencing; Tau protein expression inhibitors
-
Orphan Drug Status
Yes - Alzheimer's disease
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 05 Mar 2026 Biogen completes phase I trial (In volunteers) (Intrathecal, Injection) in the USA (NCT06454721)
- 02 Apr 2025 BIIB 080 receives Fast Track designation for Alzheimer's disease [Intrathecal,Injection] in USA
- 30 Jan 2025 Biogen initiates enrollment in phase I trial (In volunteers) (Intrathecal, Injection) (NCT06454721)